ONCOSIL MEDICAL LTD DISCLOSURECurrent Reports (8-K / ad hoc)

OSL Secures $5.6 million from Major Institutional Investors

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113 AUSTRALIA TELEPHONE +61 2 8935 9629 WEB www.oncosil.com 1 ASX Announcement 7 September 2026 OncoSil Medical Secures $5.6 million from Major Institutional Investors Key highlights • OncoSil Medical has received commitments for a total of $5.6 million from its three largest institutional investors Pengana High Conviction Equities Fund, Regal Partners and Australian Ethical Investments • Comprises a $4.0 million placement and early exercise of OncoSil Medical listed options ($1.6 million) at a 9.9% premium to last traded price • Funds will support the commercial launch of the OncoSil™ device in the United States and Australia, following recent U.S. Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) approvals • Strengthens pro-forma cash and cash equivalents to $12.1 million1 • The G-BA funded study, two additional European regulatory filings and Sydney manufacturing commencement is anticipated to be delivered in 1H FY27 Sydney, Australia – 7 September 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company developing targeted radiation therapies for difficult-to-treat cancers, is pleased to announce that it has received commitments for a total of $5.6 million in new capital from a combination of a share placement and early exercise of listed options (ASX:OSLOE) from the Company’s three largest shareholders Pengana High Conviction Equities Fund, Regal Partners and Australian Ethical Investments. A total of $4.0 million by way of a placement at $1.00, representing a 9.9% premium to the last closing price on 7 September 2026 and through the issue of 4.0 million shares in accordance with the Company’s existing placement capacity under ASX Listing Rule 7.1 and approximately $1.6 million through the exercise of approximately 1.8 million OSLOE listed options at $0.90. Allotment and issue of the placement shares and shares resulting from the exercise of the options is expected to occur on 10 September 2026, with normal trading expected to commence on 11 September 2026. Dr Thomas Duthy, Chairman of OncoSil Medical, said: “We thank our three largest institutional investors for their confidence in our business and outlook. With both FDA